Alumis Inc

Explore the latest FDA‑approved oncology drugs—Tegafur‑S‑1, CAR‑T, Pembrolizumab + chemo, and TDM‑1—showing survival gains, safety, and precision‑medicine insights.

Foresite Capital’s recent purchase of Alumis Inc. shares signals strong institutional confidence in its TYK2 inhibitor pipeline, offering investors insight into a clinical‑stage biotech’s future prospects.